Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Ryan Memmer
08.02.24 -- FDA Finalizes Guidance About Delaying, Denying, Limiting, Or Refusing An Inspection
Advances in drug and biologics discovery have allowed the development of more sophisticated and highly targeted therapeutics, with active ingredients becoming increasingly costly to manufacture. Handling high-value, complex active ingredients requires a mindset that rigorously protects against unnecessary loss of active ingredient.
Factors In Developing Injectable Drug Placebo Formulations For Pharmaceutical Clinical Trials
Article | January 9, 2024 By Ryan Memmer and William Powers, Singota Designed and conducted properly, placebo-controlled clinical trials can provide proof a new drug is effective. Proper and complete understanding of development practices for placebos is important to the execution and outcomes of clinical trials.
Factors In Developing Injectable Drug Placebo Formulations For Pharmaceutical Clinical Trials Original
Article | January 9, 2024 By Ryan Memmer and William Powers, Singota Designed and conducted properly, placebo-controlled clinical trials can provide proof a new drug is effective. Proper and complete understanding of development practices for placebos is important to the execution and outcomes of clinical trials.
Developmental Testing Of IV Solutions
By Ryan Memmer, Supervisor Quality Control, Singota Solutions Intravenous (IV) drug administration has expanded as proteins have become increasingly complicated, interacting with the body more quickly and targeting therapeutic areas more precisely. To avoid adverse effects to patients, some drugs must be diluted and administered slowly using IV bags. Characterization of such drugs, for clinical or commercial use, requires proper execution of stability and/or compatibility studies.
Developmental Testing Of IV Solutions
Article | February 10, 2022 By Ryan Memmer, Supervisor Quality Control, Singota Solutions Intravenous (IV) drug administration has expanded as proteins have become increasingly complicated, interacting with the body more quickly and targeting therapeutic areas more precisely. To avoid adverse effects to patients, some drugs must be diluted and administered slowly using IV bags.
Developmental Testing Of IV Solutions
By Ryan Memmer, Singota Solutions Intravenous (IV) drug administration has expanded as proteins have become increasingly complicated, interacting with the body more quickly and targeting therapeutic areas more precisely. To avoid adverse effects to patients, some drugs must be diluted and administered slowly using IV bags. Characterization of such drugs, for clinical or commercial use, requires proper execution of stability and/or compatibility studies.
10.18.21 -- C>'s: 6 Challenges To Solve
By Paul Stroemer and Paolo Siciliano, PA Consulting This past year has seen remarkable progress in the growth of cell and gene therapies. While advances in cell reprogramming, genetic editing, and manufacturing mean affordable cell and gene therapies for a range of diseases and uses, the go-forward path will require planning around these six major issues. The clinical trials status quo is a roadblock. They're slow, they're inefficient, and they're expensive.
01.13.21 -- Managing Quality, cGMP Compliance Capability Of CMOs
By Matthew Pillar, editor, BioProcess Online In its quest to produce affordable, scalable lentiviral-based gene therapies, AVROBIO is applying concepts from small molecule, biologics, and transplant technologies to pioneer automated gene therapy manufacturing systems. By Grant Mordue, Pro-Active GMP Consulting Ltd.
10.12.20 -- Are Dry Powder Biologics Ready For Primetime?
By Matthew Pillar, editor, BioProcess Online A new approach to freezing biopharmaceuticals into fine, dry powders holds promise for flexible therapeutic form factors, efficacy improvements, and supply and distribution chain efficiencies. It's a particularly timely development in the age of COVID-19.
Analytical Instrumentation – Advancing And Maintaining A CDMO's Capabilities
By Ryan Memmer, Pharmaceutical Scientist, QC/Development Laboratory, Singota Solutions Contract Development and Manufacturing Organizations (CDMOs) in the pharmaceutical/biotech industry rely heavily on state-of-the-art instrumentation to bring their client’s products from drug development through drug manufacturing to the patient.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Ryan
Contact Ryan, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack